IL303610A - GUCY2C binding molecules and their uses - Google Patents

GUCY2C binding molecules and their uses

Info

Publication number
IL303610A
IL303610A IL303610A IL30361023A IL303610A IL 303610 A IL303610 A IL 303610A IL 303610 A IL303610 A IL 303610A IL 30361023 A IL30361023 A IL 30361023A IL 303610 A IL303610 A IL 303610A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
gucy2c
antibody
Prior art date
Application number
IL303610A
Other languages
English (en)
Hebrew (he)
Inventor
Ling He
Lin Wang
Wei Wang
Original Assignee
Parasol Biotech Ltd
Ling He
Lin Wang
Wei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parasol Biotech Ltd, Ling He, Lin Wang, Wei Wang filed Critical Parasol Biotech Ltd
Publication of IL303610A publication Critical patent/IL303610A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL303610A 2020-12-17 2021-12-16 GUCY2C binding molecules and their uses IL303610A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020137164 2020-12-17
PCT/CN2021/138845 WO2022127871A1 (en) 2020-12-17 2021-12-16 Gucy2c binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
IL303610A true IL303610A (en) 2023-08-01

Family

ID=82060074

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303610A IL303610A (en) 2020-12-17 2021-12-16 GUCY2C binding molecules and their uses

Country Status (15)

Country Link
US (1) US20240059794A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263615A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023554467A (cg-RX-API-DMAC7.html)
KR (1) KR20230131183A (cg-RX-API-DMAC7.html)
CN (2) CN118146381A (cg-RX-API-DMAC7.html)
AU (1) AU2021404641A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023011658A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205007A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001665A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009279A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230245A (cg-RX-API-DMAC7.html)
EC (1) ECSP23053774A (cg-RX-API-DMAC7.html)
IL (1) IL303610A (cg-RX-API-DMAC7.html)
MX (1) MX2023006969A (cg-RX-API-DMAC7.html)
WO (1) WO2022127871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027815A1 (zh) * 2022-08-05 2024-02-08 江苏恒瑞医药股份有限公司 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
CN115894697B (zh) * 2022-12-09 2023-08-29 华道(上海)生物医药有限公司 一种抗鸟苷酸环化酶2c的纳米抗体及其应用
WO2026086785A1 (en) * 2024-10-21 2026-04-30 Shenzhen Wondercel Biotechnology Limited Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
US9156915B2 (en) * 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
HRP20191690T1 (hr) * 2012-04-27 2019-12-27 Millennium Pharmaceuticals, Inc. Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único
US11525010B2 (en) * 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
US11981920B2 (en) * 2018-12-04 2024-05-14 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell with enhanced migration capability

Also Published As

Publication number Publication date
KR20230131183A (ko) 2023-09-12
CO2023009279A2 (es) 2023-07-21
CR20230245A (es) 2023-09-01
ECSP23053774A (es) 2023-09-29
WO2022127871A1 (en) 2022-06-23
JP2023554467A (ja) 2023-12-27
BR112023011658A2 (pt) 2023-10-17
EP4263615A1 (en) 2023-10-25
CN116917329A (zh) 2023-10-20
CL2023001665A1 (es) 2024-01-12
AU2021404641A9 (en) 2024-09-19
CN118146381A (zh) 2024-06-07
AU2021404641A1 (en) 2023-06-29
CA3205007A1 (en) 2022-06-23
EP4263615A4 (en) 2025-04-30
MX2023006969A (es) 2023-08-25
US20240059794A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US20230192841A1 (en) Claudin18.2 binding moieties and uses thereof
WO2024022512A1 (en) Claudin-6 binding moieties and uses thereof
US20230192883A1 (en) Cd19 binding molecules and uses thereof
JP7747645B2 (ja) グリピカン-3(gpc3)を標的化する抗体及びキメラ抗原受容体並びにその使用方法
IL293862A (en) Single domain antibodies and chimeric antigen receptors directed to bcma and methods of use thereof
CN113185615A (zh) 靶向bcma的嵌合抗原受体及其使用方法
WO2022127871A1 (en) Gucy2c binding molecules and uses thereof
WO2024041650A1 (en) Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2022012682A1 (en) Cd22 binding molecules and uses thereof
WO2025067338A1 (en) Dll3 binding moieties and uses thereof
WO2022012680A1 (en) Cd20 binding molecules and uses thereof
US20260091061A1 (en) Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
WO2026103881A1 (en) Bcma binding moieties and uses thereof
EA049821B1 (ru) Связывающие gucy2c молекулы и их применение